Navigation Links
Embryonic Stem Cells Treated With Growth Factor Reverse Hemophilia In Mice: UNC Researchers

"putative endoderm precursors," or PEPs. Endoderm refers to the inner layer of early embryonic cells that develops into the digestive and respiratory systems.

"Not only do ES cells differentiate into PEPs, they also engraft, persist, differentiate further and then function following injection, resulting in the persistent production of factor IX protein that can only come from a hepatocyte (liver cell) and hemophilia reversal," said study lead author Dr. Jeffrey H. Fair, associate professor of surgery and division chief of abdominal transplant surgery.

Moreover, he said, the PEP cells robustly engraft within the liver and were not recognized by the immune system as foreign.

"Within a few weeks, PEPs became hepatocytes," Fair added. "They went from something that is a very early grandparent of the hepatocyte to becoming hepatocytes. After 115 days, nearly four months after injection, mice still produced factor IX without immune suppression. This occurred even in mice that were a complete immunologic tissue mismatch to the PEPs. In addition, the incidence of teratomas was low."

The researchers believe this study demonstrates the power of multidisciplinary collaboration, said co-lead author Dr. Bruce A. Cairns, assistant professor of surgery and director of research in the N.C. Jaycee Burn Center. "This approach may not only be beneficial, but required in order to solve complex problems such as these in medicine."

Although a number of questions need to be answered, this work has great potential for future applications, not only as a novel therapeutic possibility for hemophilia but also for other genetic or acquired diseases of the liver, said senior co-author Dr. Jeffery A. Frelinger, Kenan professor and chairman of microbiology and immunology.

"The data published in this study shows that embryonic stem cells partially differentiated, are able to remain in the liver and be functional without apparent immunological rejectio
'"/>

Source:University Of North Carolina At Chapel Hill


Page: 1 2 3

Related biology news :

1. Transplantation Of Monkey Embryonic Stem Cells Reverses Parkinson Disease In Primates
2. UCSD Discovery Shows How Embryonic Stem Cells Perform Quality Control Inspections
3. Embryonic stem cells accrue genetic changes
4. Embryonic selection of sex avoids conceiving blind children
5. Embryonic stem cells do better on bumpy nanoscale mattress
6. Embryonic patterning makes the feathers fly
7. Jump-starting T Cells In Skin Cancer
8. Emory Study Tests Bone Marrow Stem Cells to Improve Circulation in Legs
9. Fundamental Finding Yields Insight into Stem Cells, Cancer; Opens Door to Drug Discovery
10. Weill Cornell Research Reveals Secrets Of Trafficking Within Cells
11. First-ever Compounds To Target Only Metastatic Cells Are Highly Effective Against Breast, Prostate, And Colon Cancers
Post Your Comments:
Breaking Biology News(10 mins):MSU researcher unveils new approach to treat lower back pain 2National Instruments and DENSO Robotics Collaborate to Address New Applications in Industrial Robotics 2National Instruments and DENSO Robotics Collaborate to Address New Applications in Industrial Robotics 3National Instruments and DENSO Robotics Collaborate to Address New Applications in Industrial Robotics 4Superior offspring without genetic modification 2Johns Hopkins leads first 16 patient multicenter domino donor kidney transplant 51007 1Johns Hopkins leads first 16 patient multicenter domino donor kidney transplant 51007 2Johns Hopkins leads first 16 patient multicenter domino donor kidney transplant 51007 3DaVitas Award Winning Training Program for New Teammates Reaches Milestone With 100th DaVita Academy in Baltimore Maryland 51006 1DaVitas Award Winning Training Program for New Teammates Reaches Milestone With 100th DaVita Academy in Baltimore Maryland 51006 2Denosumab Demonstrates Superiority Over Zometa 28R 29 in Pivotal Phase 3 Head to Head Trial in Breast Cancer Patients With Bone Metastases 4698 1Denosumab Demonstrates Superiority Over Zometa 28R 29 in Pivotal Phase 3 Head to Head Trial in Breast Cancer Patients With Bone Metastases 4698 2Denosumab Demonstrates Superiority Over Zometa 28R 29 in Pivotal Phase 3 Head to Head Trial in Breast Cancer Patients With Bone Metastases 4698 3Denosumab Demonstrates Superiority Over Zometa 28R 29 in Pivotal Phase 3 Head to Head Trial in Breast Cancer Patients With Bone Metastases 4698 4Denosumab Demonstrates Superiority Over Zometa 28R 29 in Pivotal Phase 3 Head to Head Trial in Breast Cancer Patients With Bone Metastases 4698 5Denosumab Demonstrates Superiority Over Zometa 28R 29 in Pivotal Phase 3 Head to Head Trial in Breast Cancer Patients With Bone Metastases 4698 6Denosumab Demonstrates Superiority Over Zometa 28R 29 in Pivotal Phase 3 Head to Head Trial in Breast Cancer Patients With Bone Metastases 4698 7Denosumab Demonstrates Superiority Over Zometa 28R 29 in Pivotal Phase 3 Head to Head Trial in Breast Cancer Patients With Bone Metastases 4698 8